Prognostic importance of fibroblast growth factor-23 in dialysis patients.

Introduction. In this study, we aimed to demonstrate the correlation of FGF-23 levels with bone-mineral metabolism, anemia, and the treatment in dialysis patients. Methods. Eighty-nine patients with similar age, gender, dialysis duration, and dialysis adequacy who were receiving hemodialysis replacement therapy for at least 6 months were included in the study. Serum iron, iron binding capacity, ferritin, hemoglobin (Hb), hematocrit (Htc), calcium (Ca), phosphorus (P), intact parathormone (iPTH), and FGF-23 levels were studied. In addition, active vitamin D and phosphate binders calcimimetic therapies that patients have received in the last 6 months were recorded. Results. It was determined that there was a positive correlation between serum FGF-23 values and PTH values (P < 0, 01) and Ca∗P values (P < 0, 01). A positive correlation was found between serum FGF-23 values and Ca values at a rate of 24,6% (P < 0, 05) and between P values at a rate of 59,1% (P < 0, 01). A positive correlation was determined between serum FGF-23 values and hemoglobin (Hb) values (P < 0, 05) and hematocrit (Htc) values (P < 0, 05). In multivariate analysis, no significant correlation was found between serum FGF-23 levels and Hb and Htc. Conclusion. The effects of high serum FGF-23 levels on different parameters may be correlated with the development of refractory secondary hyperparathyroidism.